{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:59:18Z","timestamp":1780333158913,"version":"3.54.1"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81760851"],"award-info":[{"award-number":["81760851"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011785","name":"Science and Technology Department of Guangxi Zhuang Autonomous","doi-asserted-by":"publisher","award":["2018GXNSFGA281002"],"award-info":[{"award-number":["2018GXNSFGA281002"]}],"id":[{"id":"10.13039\/501100011785","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011833","name":"Guangxi University of Chinese Medicine","doi-asserted-by":"publisher","award":["2012116"],"award-info":[{"award-number":["2012116"]}],"id":[{"id":"10.13039\/501100011833","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012556","name":"Sichuan Youth Science and Technology Foundation","doi-asserted-by":"publisher","award":["2020JDTD0022"],"award-info":[{"award-number":["2020JDTD0022"]}],"id":[{"id":"10.13039\/100012556","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Hepatic fibrosis is a health challenge due to the absence of satisfactory therapy, especially at the cirrhosis stage. Dahuang Zhechong pill (DHZCP)-based therapy is reportedly a successful treatment for hepatic fibrosis and is even beneficial for the treatment of cirrhosis. Hence, a systematic review and clinical evidence assessment of DHZCP-based therapy should be performed, and clinical recommendations based on its efficacy for the treatment of hepatic fibrosis should be generated. With respect to potential indicators, the comparative value of the hepatic function, spleen thickness, and portal vein internal diameter should be evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>PubMed, the Excerpta Medica Database, the Cochrane Library, the Web of Science, the WanFang Database, the Chinese Scientific Journal Database, and the Chinese National Knowledge Infrastructure database were searched to identify clinical trials. Three subgroup analyses were performed based on the stage of disease, medication use, and the course of treatment. Statistical analyses were performed using Review Manager 5.4.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 18 studies including 1,494 patients were evaluated. The DHZCP-based therapy was effective in reducing the plasma levels of hyaluronic acid, and laminin, procollagen III, and IV collagen were also reduced irrespective of the hepatitis stage or the presence of hepatic cirrhosis. Abnormalities in alanine aminotransferase, aspartate aminotransferase, albumin, and total bilirubin were reversed. A 6-month course of treatment was the most beneficial DHZCP-based therapy regimen. Alanine aminotransferase improvement was more obvious in patients with cirrhosis, and alanine aminotransferase was reduced significantly in patients with hepatic cirrhosis. With respect to pharmacological mechanisms, DHZCP-based therapy could inhibit hepatic stellate cell growth and activation, reduce inflammation, and prevent extracellular matrix formation. Hepatic portal hypertension and splenomegaly were ameliorated significantly in the DHZCP-based therapy group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Dahuang Zhechong pill-based therapy has demonstrated efficacy as a treatment for hepatic fibrosis and cirrhosis. A 6-month course of treatment is the recommended option for DHZCP-based therapy in clinical practice. The combination of DHZCP-based therapy and entecavir is a favorable treatment for hepatic cirrhosis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.920062","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T05:02:51Z","timestamp":1665723771000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["A meritorious integrated medical regimen for hepatic fibrosis and its complications via the systematic review and meta-analysis for Dahuang Zhechong pill-based therapy"],"prefix":"10.3389","volume":"9","author":[{"given":"Zhen","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinfeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqi","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingquan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaihua","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linzhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuantao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewen","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaobo","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1097\/MCG.0000000000000208","article-title":"The epidemiology of cirrhosis in the united states: A population-based study.","volume":"49","author":"Scaglione","year":"2015","journal-title":"J Clin Gastroenterol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jhep.2012.12.005","article-title":"The burden of liver disease in Europe: A review of available epidemiological data.","volume":"58","author":"Blachier","year":"2013","journal-title":"J Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1111\/liv.12884","article-title":"Health disparities in liver disease in sub-Saharan Africa.","volume":"35","author":"Spearman","year":"2015","journal-title":"Liver Int."},{"key":"B4","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1136\/gutjnl-2014-306842","article-title":"Pathobiology of liver fibrosis: A translational success story.","volume":"64","author":"Lee","year":"2015","journal-title":"Gut."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040875","article-title":"Liver fibrosis: Mechanistic concepts and therapeutic perspectives.","volume":"9","author":"Roehlen","year":"2020","journal-title":"Cells-Basel."},{"key":"B6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/liv.13641","article-title":"Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B.","author":"Buti","year":"2018","journal-title":"Liver Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3736\/jcim20110612","article-title":"[Effects of chinese herbal medicine yiguanjian decoction on collagen metabolism of hepatic tissues in rats with ccl4-induced liver fibrosis].","volume":"9","author":"Wang","year":"2011","journal-title":"Zhong Xi Yi Jie He Xue Bao."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.105765","article-title":"Research progress on the anti-hepatic fibrosis action and mechanism of natural products.","volume":"75","author":"Shan","year":"2019","journal-title":"Int Immunopharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jep.2018.11.027","article-title":"Chinese medicine CGA formula ameliorates liver fibrosis induced by carbon tetrachloride involving inhibition of hepatic apoptosis in rats.","volume":"232","author":"Tian","year":"2019","journal-title":"J Ethnopharmacol."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101600","article-title":"Curcumin blunts epithelial-mesenchymal transition of hepatocytes to alleviate hepatic fibrosis through regulating oxidative stress and autophagy.","volume":"36","author":"Kong","year":"2020","journal-title":"Redox Biol."},{"key":"B11","author":"Barolet","year":"1990","journal-title":"Chinese herbal medicine: formulas &amp; strategies."},{"key":"B12","author":"Xu","year":"2021","journal-title":"Chinese Medicinal Formulas."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2998825","article-title":"Postoperative effect observation and clinical study of dahuang zhechong pills from jingui yaolue in treating patients with early-to-mid prostate cancer undergoing radical resection.","volume":"2022","author":"Hou","year":"2022","journal-title":"Comput Intell Neurosci."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/4354054","article-title":"Efficacy and safety of dahuang zhechong pill in silicosis: a randomized controlled trial.","volume":"2021","author":"Tang","year":"2021","journal-title":"Evid Based Complement Alternat Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3736\/jcim20090214","article-title":"[Clinical application of Dahuang Zhechong Pill in gynecology].","volume":"7","author":"Yuan","year":"2009","journal-title":"J Chin Integrative Med."},{"key":"B16","first-page":"176","article-title":"Effect of Dahuang Zhechong pill on cross-linking of lipopolysaccharide with TLR4 in hepatic stellate cells.","volume":"40","author":"Liu","year":"2015","journal-title":"Guangdong Med J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1007\/s00330-020-06665-4","article-title":"Assessment of liver fibrosis severity using computed tomography-based liver and spleen volumetric indices in patients with chronic liver disease.","volume":"30","author":"Son","year":"2020","journal-title":"Eur Radiol."},{"key":"B18","first-page":"1109","article-title":"Clinical effects of Dahuang Zhechong pill combined with tenofovir for the treatment of chronic hepatitis B liver fibrosis.","volume":"43","author":"Guo","year":"2020","journal-title":"Chin J Postgra Med."},{"key":"B19","article-title":"Clinical study of Dahuang Zhechong pill in combination with entecavir for hepatitis B cirrhosis.","volume":"4","author":"Pan","year":"2019","journal-title":"Mod Dig Intervent."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"B21","first-page":"1003","article-title":"Clinical observation of entecavir combined with Dahuang Zhechong pill in the treatment of hepatitis B cirrhosis.","volume":"32","author":"Hong","year":"2019","journal-title":"J Med Theo Prac."},{"key":"B22","first-page":"3141","article-title":"Effect of Dahuang Zhechong Capsule combined with entecavir on liver fibrosis and T-cell subsets in pa-tients with hepatitis B cirrhosis.","volume":"40","author":"Yao","year":"2019","journal-title":"Guangdong Med J."},{"key":"B23","first-page":"1048","article-title":"Effect of Dahuang Zhechong pill combination antiviral therapy on serum viral replication indexes and immune and inflammatory indexes in patients with chronic hepatitis B cirrhosis.","volume":"23","author":"Huang","year":"2017","journal-title":"J Hainan Med Coll."},{"key":"B24","first-page":"575","article-title":"Efficacy of Dahuang Zhechong pill in combination with entecavir in the treatment of chronic hepatitis B cirrhosis.","volume":"24","author":"Zhang","year":"2016","journal-title":"Chin J Integr Tradit West Med Dig."},{"key":"B25","first-page":"258","article-title":"Clinical study of Dahuang Zhechong pill in combination with entecavir for hepatitis B liver fibrosis.","volume":"21","author":"Zhou","year":"2016","journal-title":"Lingnan J. Emerg Med."},{"key":"B26","first-page":"237","article-title":"34 cases of liver fibrosis in chronic hepatitis B treated with Dahuang Zhechong Capsule.","volume":"24","author":"Liu","year":"2013","journal-title":"China Pharm."},{"key":"B27","first-page":"56","article-title":"Dahuang Zhechong pill combined with western medicine for 66 cases of hepatitis B cirrhosis in compensated stage.","volume":"33","author":"Liu","year":"2013","journal-title":"Henan Tradit Med J."},{"key":"B28","first-page":"51","article-title":"Dahuang Zhechong pill combined with interferon-\u03b1 for the treatment of chronic hepatitis B in 30 cases.","volume":"25","author":"Feng","year":"2011","journal-title":"J Pract Tradit Chin Intern Med."},{"key":"B29","first-page":"47","article-title":"Efficacy of adefovir combined with Dahuang Zhechong pill in the treatment of active hepatitis B cirrhosis.","author":"Cheng","year":"2009","journal-title":"Chin Rem Clin."},{"key":"B30","first-page":"129","article-title":"Clinical observation of Dahuang Zhechong pill in the treatment of viral hepatitis cirrhosis.","volume":"28","author":"Liang","year":"2009","journal-title":"Chin Foreign Med Treat."},{"key":"B31","first-page":"611","article-title":"Efficacy of Adefovir combined with Dahuang Zhechong pill in the treatment of hepatitis B cirrhosis.","volume":"17","author":"Zhang","year":"2008","journal-title":"J Emerg Tradit Chin Med."},{"key":"B32","first-page":"695","article-title":"Dahuang Zhechong pill with lamivudine for chronic hepatitis B liver fibrosis.","volume":"36","author":"Miao","year":"2007","journal-title":"J Zhejiang Chin Med Univ."},{"key":"B33","first-page":"808","article-title":"Clinical efficacy of Dahuang Zhechong pill against liver fibrosis.","volume":"17","author":"Xu","year":"2006","journal-title":"Lishizhen Med Mater Med Res."},{"key":"B34","article-title":"Clinical study of Dahuang Zhechong Capsule in the treatment of chronic hepatitis B.","volume":"26","author":"Tian","year":"2003","journal-title":"J Jining Med Coll."},{"key":"B35","article-title":"The efficacy of Dahuang Zhechong pill in preventing and treating liver fibrosis in chronic viral hepatitis B.","volume":"8","author":"Shen","year":"2002","journal-title":"Hubei J Tradit Chin Med."},{"key":"B36","first-page":"98","article-title":"Effect of Dahuang Zhechong pill on liver fibrosis indexes in chronic hepatitis.","volume":"11","author":"Lin","year":"2001","journal-title":"Chin J Integr Tradit West Med Liver Dis."},{"key":"B37","year":"2020","journal-title":"Chinese pharmacopoeia."},{"key":"B38","first-page":"2353","article-title":"Determination of the content of 17 quality markers in Dahuang Zhechong Pill.","volume":"32","author":"Fu","year":"2021","journal-title":"China Pharm."},{"key":"B39","article-title":"Investigation on the Characteristic Components of Dahuang Zhechong Pill Based on High-Performance Liquid Chromatography (HPLC) Fingerprint.","volume":"14","author":"Li","year":"2019","journal-title":"Nat Prod Commun."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2020.122200","article-title":"Simultaneous determination of nineteen compounds of Dahuang zhechong pill in rat plasma by UHPLC-MS\/MS and its application in a pharmacokinetic study.","volume":"1151","author":"Wu","year":"2020","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"B41","first-page":"54","article-title":"Simultaneous determination of six ingredients in Dahuang Hibiscus Pill by HPLC-PDA method.","volume":"30","author":"Zhang","year":"2019","journal-title":"China Pharm."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.3748\/wjg.v9.i11.2497","article-title":"Influence factors of serum fibrosis markers in liver fibrosis.","volume":"9","author":"Tao","year":"2003","journal-title":"World J Gastroenterol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"6769","DOI":"10.3748\/wjg.v21.i22.6769","article-title":"Portal vein thrombosis in cirrhosis: Controversies and latest developments.","volume":"21","author":"Harding","year":"2015","journal-title":"World J Gastroenterol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ctim.2014.12.011","article-title":"Effect of Dahuang zhechong formula on liver fibrosis in patients with chronichepatitis B: a meta-analysis.","volume":"23","author":"Wei","year":"2015","journal-title":"Complement Ther Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.hbpd.2018.04.003","article-title":"Hepatic fibrosis: It is time to go with hepatic stellate cell-specific therapeutic targets.","volume":"17","author":"Ezhilarasan","year":"2018","journal-title":"Hepatobiliary Pancreat Dis Int."},{"key":"B46","doi-asserted-by":"publisher","first-page":"7312","DOI":"10.3748\/wjg.v20.i23.7312","article-title":"Pathogenesis of liver cirrhosis.","volume":"20","author":"Zhou","year":"2014","journal-title":"World J Gastroenterol."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19103104","article-title":"Danger-Associated molecular patterns (DAMPs): Molecular triggers for sterile inflammation in the liver.","volume":"19","author":"Mihm","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/embo-reports\/kvf198","article-title":"The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway.","volume":"3","author":"Gardella","year":"2002","journal-title":"EMBO Rep."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1084\/jem.20042614","article-title":"The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion.","volume":"201","author":"Tsung","year":"2005","journal-title":"J Exp Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/jvh.12152","article-title":"Enhanced high-mobility group box 1 (HMGB1) modulates regulatory T cells (Treg)\/T helper 17 (Th17) balance via toll-like receptor (TLR)-4-interleukin (IL)-6 pathway in patients with chronic hepatitis B.","volume":"21","author":"Li","year":"2014","journal-title":"J Viral Hepat."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/nm1663","article-title":"TLR4 enhances TGF-beta signaling and hepatic fibrosis.","volume":"13","author":"Seki","year":"2007","journal-title":"Nat Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"7082","DOI":"10.1074\/jbc.M113.543769","article-title":"Transcriptional repression of the transforming growth factor beta (TGF-beta) Pseudoreceptor BMP and activin membrane-bound inhibitor (BAMBI) by Nuclear Factor kappaB (NF-kappaB) p50 enhances TGF-beta signaling in hepatic stellate cells.","volume":"289","author":"Liu","year":"2014","journal-title":"J Biol Chem."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1042\/CS2019110263","article-title":"Healing gone wrong: Convergence of hemostatic pathways and liver fibrosis?","volume":"134","author":"Davis","year":"2020","journal-title":"Clin Sci (Lond)."},{"key":"B54","first-page":"739","article-title":"Rhein inhibits liver fibrosis induced by carbon tetrachloride in rats.","volume":"23","author":"Guo","year":"2002","journal-title":"Acta Pharmacol Sin."},{"key":"B55","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jtcm.2018.04.007","article-title":"Effect of Dahuang Zhechong pills on long non-coding RNA growth arrest specific 5 in rat models of hepatic fibrosis.","volume":"38","author":"Gong","year":"2018","journal-title":"J Tradit Chin Med."},{"key":"B56","author":"Zhao","year":"2004","journal-title":"Experimental study on the anti-liver injury effect of rhubarb acid and its mechanism."},{"key":"B57","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.freeradbiomed.2020.05.012","article-title":"Baicalin promotes liver regeneration after acetaminophen-induced liver injury by inducing NLRP3 inflammasome activation.","volume":"160","author":"Shi","year":"2020","journal-title":"Free Radic Biol Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/jcb.29378","article-title":"Dahuang Zhechong pill attenuates CCl4-induced rat liver fibrosis via the PI3K-Akt signaling pathway.","volume":"121","author":"Gong","year":"2020","journal-title":"J Cell Biochem."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2019.112442","article-title":"Advances in anti hepatic fibrotic therapy with Traditional Chinese Medicine herbal formula.","volume":"251","author":"Li","year":"2020","journal-title":"J Ethnopharmacol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3109\/13880209.2011.604333","article-title":"Evaluation of the liver protection and toxicity of Da-Huang-Zhe-Chong pill in rats.","volume":"50","author":"Xing","year":"2012","journal-title":"Pharm Biol."},{"key":"B61","first-page":"57","article-title":"Effect of adefovir dipivoxil capsules combined with Dahuang Zhechong capsules in the treatment of hepatic fibrosis","volume":"4","author":"Dingchun","year":"2014","journal-title":"Chin Med Pharm."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.920062\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T05:03:24Z","timestamp":1665723804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.920062\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":61,"alternative-id":["10.3389\/fmed.2022.920062"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.920062","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]},"article-number":"920062"}}